AstraZeneca vaccine

In Spain, the AstraZeneca vaccine has been administered to people up to the age of 55.

15-03-2021Yves Herman

Spain is to suspend the use of the AstraZeneca vaccine. This decision is to be communicated to regional health authorities at an extraordinary meeting of the Inter-Territorial Council for the National Health System on Monday evening. It comes after several other countries have decided to suspend the administering of the vaccine because of fears of thrombosis.

On Monday, France, Germany and Italy all announced that they were suspending the use of the vaccine as a preventive measure. Emmanuel Macron added that the French government is nevertheless awaiting opinion from the European Medicines Agency, which is expected on Tuesday.

The EMA continues to insist, however, that the benefits of the vaccine outweigh so far unproven risks.

In Spain, the vaccine has only been administered to people up to the age of 55. Suspension will represent a major setback to the goal of having 70% of the Spanish population vaccinated by the summer.


To be able to write a comment, you have to be registered and be logged in.

* Mandatory fields

Brett Dennis / Hace 11 months

Again, politics and spite against UK at the expense of public health. Why do EU citizens put up with it. Not a single clot problem apparently with AZ vaccinations in Mallorca.


Lisa / Hace 11 months

The European medicine regulator has issued a statement saying there is no reason to suspend this vaccine. They are traditionally over protective.

Given this, the suspension of vaccines appears more political than medical.

This will cost lives. It will put vaccination levels back and thus threaten the economy further. Sceptical folk will seize on this and claim vaccination isn’t safe.

None of this is good news. Tragic - at a time when we were just beginning to see a light at the end of the Covid tunnel.


Colin Allcars / Hace 11 months

The European Medicines Agency has stressed that there is "currently no indication that vaccination caused these conditions" - adding that the jab's benefits continue to outweigh the risks.

A review is being carried out into each reported incident, and the regulator says that - of almost five million people given the vaccine across Europe - there have been just 30 reports of blood clots.

An EMA statement on Monday said: "Events involving blood clots, some with unusual features such as low numbers of platelets, have occurred in a very small number of people who received the vaccine.

"Many thousands of people develop blood clots annually in the EU for different reasons. The number of thromboembolic events overall in vaccinated people seems not to be higher than that seen in the general population."